Comparative Pharmacology
Head-to-head clinical analysis: HYCODAN versus HYCOFENIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYCODAN versus HYCOFENIX.
HYCODAN vs HYCOFENIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a full mu-opioid receptor agonist; homatropine is an anticholinergic agent that reduces excessive respiratory tract secretions.
HYCOFENIX is a combination of hydrocodone, an opioid agonist, and fenix, a non-opioid analgesic. Hydrocodone binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Fenix acts through COX-2 inhibition, reducing prostaglandin synthesis and inflammation.
1 tablet (5 mg hydrocodone/1.5 mg homatropine) orally every 4 to 6 hours as needed for cough; maximum 6 tablets per 24 hours.
Hydrocodone 5-10 mg orally every 6 hours as needed for pain. Maximum single dose 10 mg; maximum daily dose 40 mg.
None Documented
None Documented
Terminal elimination half-life of hydrocodone is 3.8-5.7 hours (mean 4.5 h) in adults; clinical duration of analgesia is 4-6 hours. Half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life is 3-5 hours in healthy adults, extending to 6-8 hours in elderly patients and up to 10 hours in hepatic impairment.
Renal elimination of unchanged drug (hydrocodone: ~26%; homatropine: negligible) and glucuronide conjugates (hydrocodone: ~40% as hydromorphone and norhydrocodone). Biliary/fecal excretion accounts for ~20-30%.
Renal excretion of unchanged drug accounts for 30-40%; hepatic metabolism and biliary excretion account for 50-60%; fecal excretion <10%.
Category C
Category C
Opioid Antitussive
Opioid Antitussive